Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Biologic Therapy/Immunobiology
•
Rheumatology
•
COVID-19
•
General Rheumatology
•
Tocilizumab
•
Biologics
•
COVID-19 virus
Do you use tocilizumab for the treatment of severe COVID-19 in patients who are on other biologics for rheumatic diseases, such as rituximab?
Related Questions
What isolation policies are Rheumatology offices employing for both staff and patients diagnosed with COVID-19 given the new CDC guidelines?
How do you approach endocarditis prophylaxis for patients with rheumatic diseases undergoing invasive dental surgery and no history of joint replacement?
How do you approach initiation/continuation of biologics if there is a suspicious pulmonary nodule that requires close interval imaging (i.e every 3 or 6 months)?
Have you utilized combination biologic therapy for the treatment of rheumatic diseases?
Do you generally recommend starting nintedanib prior to immunosuppressive therapy in a patient with CTD-ILD?
What is your approach to management of methotrexate osteopathy?
What would be your approach to a patient with Scleroderma/Myositis overlap syndrome (+anti-Ku) and active inflammatory eye disease despite high dose mycophenolate?
How do you approach the timing of Rituximab during pregnancy in a patient with life or organ threatening autoimmune disease?
How do you approach management of a patient with persistent EBV infection and MAS despite treatment with Rituximab, anakinra and canakinumab?
How do you approach management of a patient with idiopathic PAH and +ANA, but no other current symptoms/signs of active rheumatologic disease?